Leadership in "therapeutic cloning" has shifted abroad while American scientists, hamstrung by political and religious opposition, make do with private or state funds in the absence of federal support.

Hrm. In the context of this op-ed, and the recent story in Science, Nicholas Kristof's latest column seems timed for effect.